You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
恒指升幅扩至逾340点 中生制药(01177.HK)首季多赚逾1倍股价创逾九个月高後倒跌近4%
阿思达克 05-25 11:01
中生制药(01177.HK)首季多赚逾1倍,麦格理将中生评级由「中性」升至「跑赢大市」,目标价升近25%至10.46元,以反映上调公司今明两年盈测62%及33%。不过,该股承过去两连涨势,今早高开近半成,升幅曾扩至7.1%报9.69元,为去年8月初以来最高无以为继,获利盘涌现,拖累股价掉头低见8.65元,现造8.71元,逆市倒跌3.7%,为最伤蓝筹,成交增至1.73亿股,涉资15.8亿元。

中生昨天收市後公布,今年首季纯利按年增近1.2倍至19.13亿人民币,每股盈利10.19分,季度股息按年维持2港仙。期内,营收按年升逾16%至72.43亿元人民币。

恒指在安踏(02020.HK)、舜宇(02382.HK)、腾讯(00700.HK)、小米(01810.HK)及药明生物(02269.HK)依次升逾2%-5%推动,升幅扩至343点或1.2%,报28,755,成交额659亿元。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account